著者：劉新宇 李佳
国家市場監督管理総局による事業者結合審査は、近年その業務量の増大が続いており、2025年における審査完了件数も前年比9.8％増の706件に達するなど、審査案件の増加傾向は依然として顕著である。こうして審査の効率化と専門性の確保・深化が課題となる中、SAMRは、2022年8月1日から3年間にわたる試行の成果を踏まえ、北京市、上海市、広東省、重慶市、陝西省これら5省市の市場監督管理機関に対し、2025年8月1日から事業者結合独占禁止審査の一部を正式に委託するようになった。
China Headquartered Company Resolves Books And Records And Internal Controls Matter
The Foreign Corrupt Practices Act has always been a law much broader than its name suggests.
Sure, the FCPA contains anti-bribery provisions which concern foreign bribery.
Sure, the FCPA’s books and records and internal controls provisions can be implicated in
ICLG – International Arbitration Laws and Regulations 2026 Guide
Duane Morris & Selvam Advises on ESDS Software Solution Limited’s IPO
见微以知萌，执一而应万——2025年度上海海关行政处罚案件分析
作者：孙兴 张文怡 职源
2025年，受地缘政治冲突、贸易保护主义抬头等多重因素影响，国际贸易环境呈现出更强的不确定性和波动性。面对复杂严峻的外部环境，我国的经济展现出强大的韧性和活力。据海关统计，2025年我国外贸进出口45.47万亿元，增长3.8%。其中，出口26.99万亿元，增长6.1%；进口18.48万亿元，增长0.5%。
China-US Alliance: Private Wealth Forum 2026 in Shanghai – Strengthening Cross-Border Insights
Cross-border wealth and estate planning have become increasingly important among high-net-worth families in the APAC region, particularly those with ties to Mainland China, Hong Kong, and the United States, as well as ties to offshore structures in the British Virgin
April 22 EVENT | SISIA U.S. Investment Immigration Forum
Greenberg Traurig Immigration & Compliance attorney Luna Ma served as a panelist during Phase I of the Shanghai Immigration Service Industry Association.
April 22 EVENT | SISIA U.S. Investment Immigration Forum
Greenberg Traurig Immigration & Compliance attorney Luna Ma served as a panelist during Phase I of the Shanghai Immigration Service Industry Association.
When AI Becomes Accomplice: Shanghai Court Holds Developers Criminally Liable for Chatbot Content
Editor’s Note: Criminal accountability for AI developers is no longer theoretical. A landmark ruling from the Xuhui District People’s Court in Shanghai makes clear that those who configure AI systems to bypass ethical safeguards and produce harmful content can be
FDA Approves Shanghai Henlius’s Interchangeable Pertuzumab Biosimilar
On November 13, 2025, the FDA approved Shanghai Henlius Biologics Co. Ltd.’s POHERDY (pertuzumab-dpzb) as an interchangeable biosimilar to Genentech’s PERJETA (pertuzumab). This is the first pertuzumab biosimilar to receive FDA approval.
Pertuzumab is a HER2 inhibitor that is administered